A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis

BACKGROUND: Time to relapse after rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is variable, and optimal retreatment strategy has remained unclear. In AAV following rituximab induction, the study objective was to evaluate clinical and B-cell pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Jack, Vital, Edward M., Dass, Shouvik, Aslam, Aamir, Rawstron, Andy C., Savic, Sinisa, Emery, Paul, Md Yusof, Md Yuzaiful
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789753/
https://www.ncbi.nlm.nih.gov/pubmed/35095887
http://dx.doi.org/10.3389/fimmu.2021.803175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789753/
https://www.ncbi.nlm.nih.gov/pubmed/35095887
http://dx.doi.org/10.3389/fimmu.2021.803175

Ejemplares similares